36% 24% 40% 0% 20% 40% 60% 80% 100% Limited resolution and IOP risk highlight limitations of steroid eyedrops in MESI Am J Ophthalmol 2018 Jul: 191:14-22; Am J Ophthalmol. 2022 Aug:240:232-238 Good response Partial response Refractory 32% 0% 20% 40% 60% 80% 100% IOP elevation 32% of patients on Durezol drops had an IOP response that is clinically concerning In 36% of patients, topical steroids (difluprednate, Durezol) controlled the disease. In 40% of patients, the disease was refractory to steroid drops 104